Views on running a successful MedTech company.

53 blogs about the topic

Who's afraid of the big bad data?
Business Digital

Posted on 08.10.2013

Who’s afraid of the big bad data?

Two years ago in our annual report on the medtech sector, Pulse of the industry, we warned that the sector was facing a perfect storm, caused by a general shift toward value-based care, growing regulatory pressure in the US and limited resources as a result of a global downturn. Those events came to pass, with the added complication of tougher new regulatory issues in Europe. It was time, we felt, in this year’s report to see how the sector is weathering the storm.

By Patrick Flochel EMEIA Life Sciences Leader and Global Pharmaceutical Leader, E&Y


Posted on 18.09.2013

The Future of MedTech in Europe. Time to change your business model?

It’s increasingly clear that the Medical Technology (MedTech) industry is going through an unprecedented level of change. In Europe, budget pressures are impacting market access and reimbursement. Payers and providers require evidence of value at the clinical and socio-economic level. And buying processes are changing.

By Nicolas Kachaner Senior Partner and Managing Director, The Boston Consulting Group


Posted on 04.09.2013

Innovating the way we innovate

Value creation capabilities based solely on R&D investment are not generating as much growth as they used to. According to PwC’s “Operating performance in the Medtech industry: Trends and imperatives” report, which studied the performance of 56 global medtech companies, the impact of R&D on revenue growth declined at an average annual rate of 10% and the return on invested capital declined at a rate of 2% between 2005 and 2011. The impact on growth is evident by revenue growth rates declining at a rate of approximately 12% per year.

By Chris Wasden Managing Director, PricewaterhouseCoopers

Business Value

Posted on 23.07.2013

Have we got a speaker for you! Now you really cannot afford not to register for the MedTech Forum

A surprising few things have happened lately. Firstly, the weather in Belgium CAN be nice and pleasing to a Franco-Italian such as myself. Secondly, the ENVI Committee vote that was scheduled to take place on 10 July was postponed to 18 September for both the Medical Devices and In Vitro Diagnostics Directives. If I did not know better, one could think this date was chosen to coincide with our housewarming reception. All joking aside, my third surprise was the realisation that we’re already in mid-July, and it’s been a year since I’ve joined MedTech Europe, EDMA and Eucomed. Going into everything that has happened would take me too far this time, but I will reflect on the past year in my next blog, so look out for that to come out mid-August.

By Serge Bernasconi Chief Executive Officer, MedTech Europe

Access Business

Posted on 01.07.2013

Swiss assets – down with gold, up with titanium

In the past few weeks, the Swiss newspapers have been littered with an uncomfortable and poisonous prospect: the U.S. A financial force banging its chest from its modest economic recovery is demanding tax justice from Switzerland. The stable currency, neutrality and talented investment acumen that the Swiss have quietly touted to global investors has allowed them to amass some 30-40% of foreign investments. Now the tables are turning. With increasing pressure from the U.S., Switzerland is about to be forced into giving up one of its oldest and most sacred treasures – the hidden, numbered, off-shore Swiss bank accounts. So far this only seems to be relevant to U.S. account holders, but the vultures are already beginning to circle. France, Germany and the U.K. will almost certainly follow suit once the dust clears and the stage opens up for more opportunistic assaults on secret Swiss accounts.

By Sarah Moyle Head of International Relations at Medtech Switzerland

Healthcare expenses
Business Value

Posted on 20.06.2013

Medtech as a cost driver… or not?

Nowadays everyone seems convinced of the clinical benefits that medical technologies, devices and diagnostics, bring to the table. Many even recognise that our innovations bring about considerable socio-economic benefits. And yet, in the end I hear the same thing over and over again: medical technology drives the rise in healthcare expenditure.
EDMA and Eucomed have always refuted this claim and now we have research by the European Health Technology Institute (EHTI) which basically confirms two of our points of view:

By Serge Bernasconi Chief Executive Officer, MedTech Europe


Posted on 13.06.2013

Entrepreneurs and the Current European Healthcare Landscape

The healthcare landscape is changing globally and on many levels: regulatory, economic, and technological. With the strong winds of change, entrepreneurs are increasingly required to build their companies into real, sustainable and successful high growth businesses in a much shorter time to stay viable. 

Innovation is poised to play a greater role in the evolution of the healthcare market as demographic, regulatory and financial challenges play out. Yet, new product and services concepts often struggle to gain momentum in the larger institutions. Entrepreneurs, in contrast, have the freedom to develop ideas, but are faced with limited resources that can just as easily stifle their innovations. 

By Aris Constantinides Co President, 2013 Healthtech Summit

Business Value

Posted on 23.05.2013

New rules, new markets – medical devices and diagnostics’ place in a changing Europe

Judging by the weather in Belgium (currently 10° and raining) you wouldn’t say it, but it’s almost summer. Well, at least according to the calendar. And apart from the supposed good weather, summer also brings with it a host of new information on the MedTech Forum. Speakers are being confirmed, registrations coming in and preparations being made. Less than 5 months from now, we will all be seeing each other again at the event no one in our industry can afford to miss. So what does the MedTech Forum hold in store this year.

By Serge Bernasconi Chief Executive Officer, MedTech Europe

Cost cutting
Business Value

Posted on 10.04.2013

Does investing in demonstrating value help with reimbursement for new medical technologies?

The tool most commonly used to demonstrate the value of a new medical technology is the business case. Typical business cases can be thought of as falling into one of four categories. Compared with current care, the technology:

– costs less in the current year and you get what you get from current care (‘save money now’).
– costs the same and you get more than you get from current care (‘more value for current spend’).
– costs more in the current year but cost less when future savings are taken into account and you get what you get from current care (‘spend now to save later’).
– costs more but you get more (‘spend more for better quality’).

By Mark Charny Managing Director, Translucency Ltd.